Literature DB >> 21757444

Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging.

Sean J Hipp1, Emilie Steffen-Smith, Dima Hammoud, Joanna H Shih, Robyn Bent, Katherine E Warren.   

Abstract

Noninvasive evaluation using MRI is the primary means to routinely assess children with diffuse intrinsic pontine gliomas (DIPGs). However, no standard MR sequence has correlated with outcome in these patients. In this study, patients with DIPGs were assessed to determine the combined prognostic value via dynamic susceptibility contrast (DSC) MRI, single-voxel spectroscopy (SVS), multivoxel MR spectroscopy (MRS), and T1-weighted post-gadolinium imaging. Eligible patients had clinical and radiographic findings consistent with a DIPG. Imaging studies were acquired on a 1.5T MRI at various time points during each patient's course. Data were evaluated using a Cox proportional hazard model, a time-dependent covariant Cox model, a Wald test, and a Kaplan-Meier analysis. Ninety-eight studies were performed on 34 patients of median age 5.5 years. Median survival from diagnosis was 468 days. At baseline imaging only, increased ratio of choline to n-acetylaspartate (Cho:NAA) on SVS and increased perfusion on DSC-MRI each predicted shorter survival (relative risk [RR] = 1.48, P = .015 and RR = 4.91, P = .0012, respectively). When analyzing all subsequent time points, increased maximum Cho:NAA on MRS (RR = 1.45, P = .042), increased Cho:NAA on SVS (RR = 1.69, P = .003), increased perfusion (RR = 4.68, P = .0016), and the presence of enhancement (RR = 5.69, P = .022) each predicted shorter survival. Kaplan-Meier analysis showed shorter survival associated with increased perfusion at baseline (P = .0004). Increased perfusion at any time point predicts a significantly shorter survival in children with DIPG. In addition, enhancement, increased Cho:NAA on SVS, and increased maximum Cho:NAA on chemical shift imaging are predictive of shorter survival over time. Routine baseline and subsequent imaging for children with DIPG should, at minimum, incorporate DSC-MRI and SVS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757444      PMCID: PMC3145474          DOI: 10.1093/neuonc/nor076

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  14 in total

Review 1.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

Authors:  Normand Laperriere; Lisa Zuraw; Gregory Cairncross
Journal:  Radiother Oncol       Date:  2002-09       Impact factor: 6.280

2.  Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.

Authors:  K E Warren; J A Frank; J L Black; R S Hill; J H Duyn; A A Aikin; B K Lewis; P C Adamson; F M Balis
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 3.  Pediatric brain tumors.

Authors:  I F Pollack
Journal:  Semin Surg Oncol       Date:  1999-03

4.  Reproducibility of proton MR spectroscopic imaging findings.

Authors:  G Tedeschi; A Bertolino; G Campbell; A S Barnett; J H Duyn; P K Jacob; C T Moonen; J R Alger; G Di Chiro
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

5.  Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas.

Authors:  Robert M Hayward; Nicolas Patronas; Eva H Baker; Gilbert Vézina; Paul S Albert; Katherine E Warren
Journal:  J Neurooncol       Date:  2008-06-28       Impact factor: 4.130

6.  Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma.

Authors:  Darren Hargrave; Nathaniel Chuang; Eric Bouffet
Journal:  J Neurooncol       Date:  2007-10-02       Impact factor: 4.130

Review 7.  Diffuse brainstem gliomas in children: should we or shouldn't we biopsy?

Authors:  P A Leach; E J Estlin; D J Coope; J A Thorne; I D Kamaly-Asl
Journal:  Br J Neurosurg       Date:  2008-10       Impact factor: 1.596

8.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Authors:  Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

9.  Multisection proton MR spectroscopic imaging of the brain.

Authors:  J H Duyn; J Gillen; G Sobering; P C van Zijl; C T Moonen
Journal:  Radiology       Date:  1993-07       Impact factor: 11.105

Review 10.  NMR spectroscopy and pediatric brain tumors.

Authors:  Katherine E Warren
Journal:  Oncologist       Date:  2004
View more
  37 in total

1.  Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.

Authors:  Tina Young Poussaint; Sridhar Vajapeyam; Kelsey I Ricci; Ashok Panigrahy; Mehmet Kocak; Larry E Kun; James M Boyett; Ian F Pollack; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2015-10-20       Impact factor: 12.300

2.  Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.

Authors:  U Löbel; S Hwang; A Edwards; Y Li; X Li; A Broniscer; Z Patay
Journal:  Neuroradiology       Date:  2016-07-20       Impact factor: 2.804

3.  Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies.

Authors:  L A Gilligan; M D DeWire-Schottmiller; M Fouladi; P DeBlank; J L Leach
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

4.  Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.

Authors:  Ergys Subashi; Francisco J Cordero; Kyle G Halvorson; Yi Qi; John C Nouls; Oren J Becher; G Allan Johnson
Journal:  J Neurooncol       Date:  2015-10-28       Impact factor: 4.130

5.  Measurements of the pons as a biomarker of progression for pediatric DIPG.

Authors:  Emilie A Steffen-Smith; Eva H Baker; David Venzon; Shaefali Shandilya; Robyn S Bent; Katherine E Warren
Journal:  J Neurooncol       Date:  2013-10-10       Impact factor: 4.130

6.  Measuring the pons: a non-invasive biomarker for pediatric diffuse intrinsic pontine glioma.

Authors:  Katherine E Warren
Journal:  CNS Oncol       Date:  2014-05

7.  A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Patricia A Baxter; Jack M Su; Arzu Onar-Thomas; Catherine A Billups; Xiao-Nan Li; Tina Young Poussaint; Edward R Smith; Patrick Thompson; Adekunle Adesina; Pete Ansell; Vincent Giranda; Arnold Paulino; Lindsey Kilburn; Ibrahim Quaddoumi; Alberto Broniscer; Susan M Blaney; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

8.  MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry.

Authors:  James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

9.  Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma.

Authors:  Robert M Lober; Yoon-Jae Cho; Yujie Tang; Patrick D Barnes; Michael S Edwards; Hannes Vogel; Paul G Fisher; Michelle Monje; Kristen W Yeom
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

10.  Gliomas in children.

Authors:  Jane E Minturn; Michael J Fisher
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.